Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Didanosine

FDA-approved product (tablet, chewable, oral), marketed as Didanosine, Videx, Videx Ec.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Didanosine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF02

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Didanosine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis36.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Didanosine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Didanosine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

    NCT06337032 · start 2024-08-27

    Registered record
    Registry ID
    NCT06337032
    Conditions
    HIV-1-infection
    Interventions
    F/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS); F/TAF (Low Dose TOS); F/TAF (Lowest Dose TOS); E/C/F/TAF; E/C/F/TAF (Low Dose); Cobicistat (High Dose); Cobicistat (Low Dose); Cobicistat (TOS); B/F/TAF (High Dose); B/F/TAF (Low Dose); B/F/TAF (High Dose TOS); B/F/TAF (Low Dose TOS); B/F/TAF (Lowest Dose TOS); 3rd ARV Agent; Nucleos(t)ide reverse transcriptase inhibitors (NRTI); ATV; DRV; Lopinavir Boosted with ritonavir (LPV/r)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-27
    Completion
    2034-03
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionF/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS) +17 more
    PhasePhase 4
    Registry statusRecruiting

  • Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

    NCT01440569 · start 2011-09

    Registered record
    Registry ID
    NCT01440569
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    COBI; DRV; NRTIs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2015-10
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionCOBI; DRV; NRTIs
    PhasePhase 3
    Registry statusCompleted

  • Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

    NCT01363011 · start 2011-05

    Registered record
    Registry ID
    NCT01363011
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    E/C/F/TDF; COBI; ATV; DRV; NRTI
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-05
    Completion
    2015-02
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionE/C/F/TDF; COBI; ATV; DRV +1 more
    PhasePhase 3
    Registry statusCompleted

  • Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings

    NCT00091936 · start 2009-08

    Registered record
    Registry ID
    NCT00091936
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Didanosine; Efavirenz; Lamivudine; Standard TB treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-08
    Completion
    Not recorded
    Enrolment
    592

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionDidanosine; Efavirenz; Lamivudine; Standard TB treatment
    PhaseNot applicable
    Registry statusCompleted

  • Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

    NCT00708162 · start 2008-07

    Registered record
    Registry ID
    NCT00708162
    Conditions
    HIV Infection
    Interventions
    Elvitegravir; Raltegravir; EVG placebo; RAL placebo; Background regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2015-04
    Enrolment
    724

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionElvitegravir; Raltegravir; EVG placebo; RAL placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children

    NCT00364793 · start 2007-02

    Registered record
    Registry ID
    NCT00364793
    Conditions
    HIV Infections
    Interventions
    Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2013-07
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEfavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment

    NCT00332306 · start 2006-06

    Registered record
    Registry ID
    NCT00332306
    Conditions
    Tuberculosis; Human Immunodeficiency Virus Infections
    Interventions
    Didanosine, Lamivudine, Efavirenz; Didanosine, Lamivudine, Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-06
    Completion
    2011-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Human Immunodeficiency Virus Infections
    InterventionDidanosine, Lamivudine, Efavirenz; Didanosine, Lamivudine, Nevirapine
    PhasePhase 3
    Registry statusUnknown

  • Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth

    NCT00102960 · start 2005-07

    Registered record
    Registry ID
    NCT00102960
    Conditions
    HIV Infections
    Interventions
    Abacavir sulfate; Didanosine; Efavirenz; Lamivudine; Lopinavir/Ritonavir; Nevirapine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-07
    Completion
    2013-01
    Enrolment
    377

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir sulfate; Didanosine; Efavirenz; Lamivudine +3 more
    PhasePhase 3
    Registry statusCompleted

  • Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

    NCT00084136 · start 2005-05

    Registered record
    Registry ID
    NCT00084136
    Conditions
    HIV Infections
    Interventions
    Atazanavir; Didanosine (enteric-coated); Efavirenz; Emtricitabine; Emtricitabine/Tenofovir disoproxil fumarate; Lamivudine/Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-05
    Completion
    2010-05
    Enrolment
    1,571

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAtazanavir; Didanosine (enteric-coated); Efavirenz; Emtricitabine +2 more
    PhasePhase 4
    Registry statusCompleted

  • Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort

    NCT00618176 · start 2005-01

    Registered record
    Registry ID
    NCT00618176
    Conditions
    HIV Infections
    Interventions
    Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP); Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP); Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-01
    Completion
    Not recorded
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP); Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP); Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)
    PhasePhase 4
    Registry statusCompleted

  • One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine

    NCT00142337 · start 2004-12

    Registered record
    Registry ID
    NCT00142337
    Conditions
    HIV Infections
    Interventions
    Zidovudine (ZDV); Didanosine (ddI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-12
    Completion
    2009-02
    Enrolment
    244

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine (ZDV); Didanosine (ddI)
    PhasePhase 2
    Registry statusCompleted

  • Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV

    NCT00256828 · start 2004-06

    Registered record
    Registry ID
    NCT00256828
    Conditions
    HIV Infections
    Interventions
    didanosine + lamivudine + efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-06
    Completion
    2006-11
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventiondidanosine + lamivudine + efavirenz
    PhasePhase 4
    Registry statusCompleted

  • Once Daily 3TC, Efavirenz and ddI for HIV Infection

    NCT00214435 · start 2004-05

    Registered record
    Registry ID
    NCT00214435
    Conditions
    HIV Infection; AIDS
    Interventions
    once daily minimum 3-drug regimen of anti-retroviral medications
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2004-05
    Completion
    Not recorded
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; AIDS
    Interventiononce daily minimum 3-drug regimen of anti-retroviral medications
    PhasePhase 4
    Registry statusUnknown

  • To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine

    NCT00207168 · start 2004-04

    Registered record
    Registry ID
    NCT00207168
    Conditions
    AIDS
    Interventions
    Compliance
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-04
    Completion
    2006-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAIDS
    InterventionCompliance
    PhasePhase 4
    Registry statusCompleted

  • A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients

    NCT00002207 · start 2004-02

    Registered record
    Registry ID
    NCT00002207
    Conditions
    HIV Infections
    Interventions
    Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-02
    Completion
    2004-02
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionStavudine; Didanosine
    PhaseNot applicable
    Registry statusCompleted